Skip to content
12 May, 2022
Latest News
Bill Gates Says He Has COVID-19, Experiencing Mild Symptoms
WHO Studies Whether COVID-19 Has Role in Child Hepatitis Mystery
Shanghai Tightens Lockdown Despite Falling COVID Cases
  • Home
  • Contact
  • Submit News
  • Sitemap
lesothowire.com
  • Home
  • General
  • Industry
  • Judicial
  • Medicine
  • Arts
  • National
  • Literacy
  • Athletic
  • Press Releases
  • Home
  • 2022
  • May
  • 12

Day: May 12, 2022

SOLVE FSHD Anuncia Nomeação da Diretora Executiva Dra. Eva Chin e Estrutura de Financiamento Filantrópico de Empreendimento

May 12, 2022 lwadmin

VANCOUVER, British Columbia, May 11, 2022 (GLOBE NEWSWIRE) — Após o recente aclamado lançamento da SOLVE FSHD, a organização tem o prazer de anunciar formalmente a nomeação da Dra. Eva Chin como Diretora Executiva. O fundador da SOLVE

…
Africa, Press Releases, South Africa

SOLVE FSHD annonce la nomination de la Dre Eva Chin en tant que directrice exécutive et la structure de financement par « venture philanthropie »

May 12, 2022 lwadmin

VANCOUVER, Colombie-Britannique, 11 mai 2022 (GLOBE NEWSWIRE) — Suite au récent lancement acclamé de SOLVE FSHD, l’organisation a le plaisir d’annoncer officiellement la nomination de la Dre Eva Chin au poste de directrice exécutive. Le fondateur de SOLVE

…
Africa, Press Releases, South Africa

Synchronoss Finalizes Agreement with iQmetrix to Divest Digital Experience Platform and Activation Solutions

May 12, 2022 lwadmin

BRIDGEWATER, N.J., May 11, 2022 (GLOBE NEWSWIRE) — Synchronoss Technologies, Inc. (“Synchronoss” or the “Company”) (Nasdaq: SNCR), a global leader and innovator in cloud, messaging and digital products and platforms, today announced the successful completion of the sale of

…
Africa, Asean, MENA, Pakistan, Press Releases, South Africa

Reuters s’associe à la plateforme d’automatisation Sophi.io de The Globe and Mail

May 12, 2022 lwadmin

TORONTO, 11 mai 2022 (GLOBE NEWSWIRE) — Sophi.io, une plateforme d’automatisation, d’optimisation et de prédiction basée sur l’IA développée par The Globe and Mail, travaille désormais avec Reuters, la division actualités et médias de Thomson Reuters, alors qu’elle continue d’investir

…
Africa, Press Releases, South Africa

Reuters faz parceria com a Plataforma de Automação Sophi.io da The Globe and Mail

May 12, 2022 lwadmin

TORONTO, May 11, 2022 (GLOBE NEWSWIRE) — A Sophi.io, uma plataforma de automação, otimização e previsão alimentada por IA desenvolvida pela The Globe and Mail, está trabalhando com a Reuters – divisão de notícias e mídia da Thomson Reuters –

…
Africa, Press Releases, South Africa

Bridging Technology and Education: UNESCO and Huawei Deliver Campus UNESCO for Young People in 20 countries

May 12, 2022 lwadmin

SHENZHEN, China, May 12, 2022 /PRNewswire/ — UNESCO and Huawei have to date run ten Campus UNESCO sessions, focusing on technology and education and reaching students from 39 schools in 21 countries.

Campus UNESCO is an ongoing program that

…
Africa, MENA, Press Releases, South Africa

Search

Calender

May 2022
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
« Apr    

Categories

  • General
  • Industry
  • Judicial
  • Medicine
  • Arts
  • National
  • Literacy
  • Athletic
  • Press Releases

Advertisement

Latest News

Bill Gates Says He Has COVID-19, Experiencing Mild Symptoms

  • 10 May 2022

Microsoft co-founder Bill Gates said Tuesday he has tested positive for COVID-19 and is experiencing mild symptoms.Via Twitter, the billionaire...

WHO Studies Whether COVID-19 Has Role in Child Hepatitis Mystery

  • 10 May 2022

The WHO said Tuesday that 348 probable cases of hepatitis of unknown origin had been identified, as studies into the...

Shanghai Tightens Lockdown Despite Falling COVID Cases

  • 9 May 2022

Authorities in Shanghai have again tightened anti-virus restrictions, just as the city was emerging from a month of strict lockdown...

Rare Cases of COVID Returning Prompt Questions About Pfizer PillAs more doctors prescribe Pfizer’s powerful COVID-19 pill, new questions are emerging about its performance, including why a small number of patients appear to relapse after taking the drug. Paxlovid has become the go-to option against COVID-19 because of its at-home convenience and impressive results in heading off severe disease. The U.S. government has spent more than $10 billion to purchase enough pills to treat 20 million people. But experts say there is still much to be learned about the drug, which was authorized in December for adults at high risk of severe COVID-19 based on a study in which 1,000 adults received the medication. Why do some patients seem to relapse? Doctors have started reporting rare cases of patients whose symptoms return several days after completing Paxlovid’s five-day regimen of pills. That has prompted questions about whether those patients are still contagious and should receive a second course of Paxlovid. Last week, the Food and Drug Administration weighed in. It advised against a second round because there’s little risk of severe disease or hospitalization among patients who relapse. Dr. Michael Charness reported last month on a 71-year-old vaccinated patient who saw his symptoms subside but then return, along with a spike in virus levels nine days into his illness. Charness says Paxlovid remains a highly effective drug, but he wonders if it might be less potent against the current omicron variant. The $500 drug treatment was tested and approved based on its performance against the delta version of the coronavirus. “The ability to clear the virus after it’s suppressed may be different from omicron to delta, especially for vaccinated people,” said Charness, who works for Boston’s VA health system. Could some people just be susceptible to a relapse? Both the FDA and Pfizer point out that 1% to 2% of people in Pfizer’s original study saw their virus levels rebound after 10 days. The rate was about the same among people taking the drug or dummy pills, “so it is unclear at this point that this is related to drug treatment,” the FDA stated. Some experts point to another possibility: The Paxlovid dose isn’t strong enough to fully suppress the virus. Andy Pekosz of Johns Hopkins University worries that could spur mutations that are resistant to the drug. “We should really make sure we’re dosing Paxlovid appropriately because I would hate to lose it right now,” said Pekosz, a virologist. “This is one of the essential tools we have to help us turn the corner on the pandemic.” How well does Paxlovid work in vaccinated people? Pfizer tested Paxlovid in the highest-risk patients: unvaccinated adults with no prior COVID-19 infection and other health problems, such as heart disease and diabetes. The drug reduced their risk of hospitalization and death from 7% to 1%. But that doesn’t reflect the vast majority of Americans today, where 89% of adults have had at least one shot. And roughly 60% of Americans have been infected with the virus at some point. “That’s the population I care about in 2022 because that’s who we’re seeing – vaccinated people with COVID – so do they benefit?” asked Dr. David Boulware, a University of Minnesota researcher and physician. There’s no clear answer yet for vaccinated Americans, who already have a hospitalization rate far below 1%. That may come from a large ongoing Pfizer study that includes high-risk vaccinated people. No results have been published; the study is expected to wrap up in the fall. Pfizer said last year that initial results showed Paxlovid failed to meet the study’s goals of significantly resolving symptoms and reducing hospitalizations. It recently stopped enrolling anyone who’s received a vaccination or booster in the past year, a change Boulware says suggests those patients aren’t benefitting. At a minimum, the preliminary data should be released to federal officials, Boulware said. “If the U.S. government is spending billions of dollars on this medicine, what’s the obligation to release that data so that they can formulate a good policy?” Can Paxlovid be used to help prevent COVID-19 infection? Pfizer recently reported that proactively giving Paxlovid to family members of people infected with COVID-19 didn’t significantly reduce their chances of catching it. But that’s not the end of the story. Pfizer is studying several other potential benefits of early use, including whether Paxlovid reduces the length and severity of COVID-19 among households. “It’s a high bar to protect against infection, but I’d love to see data on how Paxlovid did against severe disease because it may be more effective there,” Pekosz said. Source: Voice of America

  • 9 May 2022

As more doctors prescribe Pfizer's powerful COVID-19 pill, new questions are emerging about its performance, including why a small number...

As Beijing COVID Outbreak Proves Stubborn, Mass Tests Becoming Routine

  • 8 May 2022

Millions of Beijing residents queued up for another round of COVID-19 tests Sunday as China's capital seeks to trace and...

US Workers Grapple With New Stresses as They Return to Office

  • 8 May 2022

Last summer, Julio Carmona started the process of weaning himself off a fully remote work schedule by showing up to...

Pages

  • Home
  • Contact
  • Submit News
  • Sitemap

Latest News

Bill Gates Says He Has COVID-19, Experiencing Mild Symptoms

May 10, 2022

WHO Studies Whether COVID-19 Has Role in Child Hepatitis Mystery

May 10, 2022

Search

Archive

Copyright © 2021 All rights reserved.
Magazine Plus by WEN Themes